DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Tremelimumab is an investigational drug.
There have been 147 clinical trials for Tremelimumab. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2015.
The most common disease conditions in clinical trials are Carcinoma, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are AstraZeneca, MedImmune LLC, and M.D. Anderson Cancer Center.
There are eighty-two US patents protecting this investigational drug and one international patent.
Recent Clinical Trials for Tremelimumab
|Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment||Catherine Shu||Phase 2|
|Durvalumab (MEDI4736) and Tremelimumab in Combination With Either Y-90 SIRT or TACE for Intermediate Stage HCC With Pick-the-winner Design||AstraZeneca||Phase 2|
|Durvalumab (MEDI4736) and Tremelimumab in Combination With Either Y-90 SIRT or TACE for Intermediate Stage HCC With Pick-the-winner Design||Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest||Phase 2|
Top disease conditions for Tremelimumab
Top clinical trial sponsors for Tremelimumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Tremelimumab||Start Trial||Immunoregulatory agents||Flexus Biosciences, Inc. (Princeton, NJ)||Start Trial|
|Tremelimumab||Start Trial||.beta.-glucan methods and compositions that affect the tumor microenvironment||BIOTHERA, INC. (Eagan, MN)||Start Trial|
|Tremelimumab||Start Trial||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||Start Trial|
|Tremelimumab||Start Trial||Methods of using OX40 ligand encoding polynucleotides||ModernaTX, Inc. (Cambridge, MA)||Start Trial|
|Tremelimumab||Start Trial||Intralesional (Intratumoral) dinitrochlorobenzene and associated compounds coadministered with checkpoint inhibitors for cancer treatment including treatment of metastatic cutaneous cancers||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|